In a nutshell This study investigated which was the best treatment approach before and after stem cell transplantation (SCT) for patients newly diagnosed with multiple myeloma (MM). The results showed that patients’ survival was better with CRD (cyclophosphamide, lenalidomide, and dexamethasone) chemotherapy than with CTD (cyclophosphamide,...
Read More
In a nutshell The study evaluated long-term outcomes of RVD involving lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) and risk-based maintenance therapy in patients with newly diagnosed multiple myeloma (MM). The authors found this approach to be beneficial for survival in a large group of patients. Some background RVD...
Read More
In a nutshell This study examined if subcutaneous (sc) injections of daratumumab (Darzalex) were as effective and safe as intravenous (iv) infusions for patients with relapsed or refractory multiple myeloma (MM). The authors found that sc injections were as effective as iv infusions and caused fewer side effects. Some background Daratumumab...
Read More
In a nutshell This study compared autologous stem cell transplant (SCT) to treatment with the proteasome inhibitor and chemotherapy regimen VMP (bortezomib, melphalan, prednisone) for patients with multiple myeloma (MM). It found that SCT led to better outcomes for the initial treatment of MM. Some background MM is a cancer of the plasma cells, a type...
Read More
In a nutshell This study examined if the addition of bortezomib (Velcade) to treatment with lenalidomide (Revlimid) and dexamethasone (Decadron) could improve treatment results long-term for patients with multiple myeloma (MM). The authors found that patients who received bortezomib had a longer survival long-term. Some background...
Read More
In a nutshell The study analyzed multiple clinical trials for assessing the effects of carfilzomib (Kyprolis) based treatment on kidney toxicity in patients with multiple myeloma (MM). The main finding was that kidney toxicity was an important side effect of carfilzomib based therapy. Some background Carfilzomib is largely used to treat MM. It is a...
Read More
In a nutshell The report recommends treatment management for patients with multiple myeloma (MM) during the COVID-19 pandemic. The authors suggested that therapy should be adjusted based on risks. COVID-19 testing should be done before starting therapy. Some background Patients with cancer are generally older and need special care during a pandemic (a...
Read MoreIn a nutshell This trial looked at the quality of life (QOL) of patients receiving PVd (pomalidomide, bortezomib, dexamethasone) for multiple myeloma which has returned after previous treatment. This study showed that adding pomalidomide (Pomalyst) to the Vd regimen (bortezomib, dexamethasone) did not decrease patients' QOL. Some background...
Read MoreIn a nutshell The investigators looked at the effects of cholesterol-lowering drugs from the statin group in patients with multiple myeloma (MM). The study found improved survival in patients who used statins before and after the diagnosis was made. Some background Multiple myeloma (MM) is a cancer resulting in abnormal proliferation of...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This review compared initial treatments for patients with multiple myeloma (MM) that cannot be treated with a transplant. This study found that drug regimens which included the targeted treatments bortezomib or daratumumab had better outcomes. Some background MM is a cancer involving abnormal white blood cells called myeloma cells....
Read MoreIn a nutshell The study compared the use of lenalidomide (Revlimid) and dexamethasone (Decadron) alone and with daratumumab (Darzalex) in patients with relapsed or unresponsive multiple myeloma (MM). The study showed that patients receiving all three drugs had better treatment response and survival. Some background MM is a type of cancer that affects...
Read More
